Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 25/100

INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Key Takeaway: ClaimsFiler is reminding investors with losses over $100,000 to file lead plaintiff applications in a class action lawsuit against Invivyd, Inc. The lawsuit pertains to claims of failure to disclose critical efficacy issues related to the company's lead product against the COVID-19 Omicron variant. Shares of the company, previously known as Adagio Therapeutics, saw a dramatic decline of nearly 80% after it was revealed that its product was much less effective against Omicron. Investors have until April 3, 2023, to stake their claim as lead plaintiffs in the suit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Invivyd is facing a class action lawsuit for failing to disclose material information to investors.
  • The company's lead product candidate was shown to be significantly less effective against the Omicron variant compared to previous variants.
  • The stock price plummeted nearly 80% after the adverse test results were disclosed.

Full Press Release Details

NEW ORLEANS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s shares between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
Invivyd investors should visit us at https://claimsfiler.com/cases/nasdaq-ivvd/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file claims against Invivyd, Inc.?

Investors must file lead plaintiff applications by April 3, 2023.

What period does the securities class action cover?

The Class Period runs from November 29 to December 14, 2021.

Why did Invivyd's shares drop significantly?

Shares fell nearly 80% after disclosing ADG20's low efficacy against Omicron.

What legal firm is handling the case?

Kahn Swick & Foti, LLC is available for legal discussions regarding the case.

Where can investors find more information?

Investors can visit ClaimsFiler's website for more details and assistance.

Last updated: Feb 15, 2023